Chiome Bioscience Inc. (JP:4583) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Chiome Bioscience Inc. has published promising non-clinical data for its therapeutic antibody CBA-1205, showing potential as a treatment for hepatocellular carcinoma. The study found that CBA-1205, when combined with Lenvatinib, effectively inhibited tumor growth in models, and demonstrated safety in early clinical trials. Chiome is continuing to explore CBA-1205’s potential in cancer treatment, with ongoing studies showing encouraging results.
For further insights into JP:4583 stock, check out TipRanks’ Stock Analysis page.